Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. Aspen Pharmacare Holdings Limited was founded in 1850 and is headquartered in Durban, South Africa.
Stock data | 2023 | Change |
---|---|---|
Price | $13.23 | N/A |
Market Cap | $5.88B | N/A |
Shares Outstanding | 444.24M | -1.93% |
Employees | 8.61K | N/A |
Shareholder Equity | 86.24B | 21.56% |
Valuation | 2023 | Change |
---|---|---|
P/S Ratio | 2.57 | N/A |
P/B Ratio | 0.07 | N/A |
Growth | 2023 | Change |
---|---|---|
Return on Equity | 0.0034 | N/A |
Earnings | 2023 | Change |
---|---|---|
Revenue | $2.28B | N/A |
Earnings | $293.12M | N/A |
Gross Margin | 0.4522 | N/A |
Operating Margin | 0.2197 | N/A |
Net income margin | 0.1284 | N/A |
Financial Strength | 2023 | Change |
---|---|---|
Total Assets | $7.53B | N/A |
Total Debt | $1.64B | N/A |
Cash on Hand | $611.80M | N/A |
Debt to Equity | 0.0312 | -2.24% |
Cash to Debt | 0.3727 | 34.08% |
Current Ratio | $1.92 | 30.13% |